Abstract: The present invention relates to compositions, methods, uses and kits for treating cancer. The present invention relates to methods for minimising the progression of cancer in a subject, the method comprising administering to the subject therapeutically effective amounts of chymotrypsinogen and trypsinogen, thereby minimising the progression of cancer in the subject. In particular, the methods provide a means for treating cancer by reducing the number of cancer stem cells in the subject.
Type:
Application
Filed:
June 3, 2022
Publication date:
March 23, 2023
Applicant:
Propanc Pty Ltd
Inventors:
Macarena Perán Quesada, Julian Kenyon, Juan Antonio Marchal Corrales, Maria Angel Garcia Chaves
Abstract: The present invention relates to compositions, methods, uses and kits for treating cancer. The present invention relates to methods for minimising the progression of cancer in a subject, the method comprising administering to the subject therapeutically effective amounts of chymotrypsinogen and trypsinogen, thereby minimising the progression of cancer in the subject. In particular, the methods provide a means for treating cancer by reducing the number of cancer stem cells in the subject.
Type:
Grant
Filed:
January 27, 2017
Date of Patent:
July 5, 2022
Assignee:
PROPANC PTY LTD
Inventors:
Macarena Perán Quesada, Julian Kenyon, Juan Antonio Marchal Corrales, Maria Angel Garcia Chaves
Abstract: The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumor cell to enhance cell-to-cell adhesion of tumor cells, effect proteolysis of tumor cells, or induce tumor cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumor cells.
Type:
Grant
Filed:
March 17, 2017
Date of Patent:
July 16, 2019
Assignee:
Propanc Pty Ltd
Inventors:
Julian Norman Kenyon, Paul Rodney Clayton, David Tosh, Fernando Felquer, Ralf Brandt
Abstract: The present invention relates to compositions, methods, uses and kits for treating cancer. In particular, the invention relates to compositions and methods of treating cancer in a subject comprising administering chymotrypsinogen in certain amounts, for example a weight ratio of chymotrypsinogen:trypsinogen is greater than 1:1 but less than 4:1, thereby treating cancer.
Abstract: The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.
Type:
Application
Filed:
October 22, 2010
Publication date:
October 4, 2012
Applicant:
PROPANC PTY Ltd.
Inventors:
Julian Norman Kenyon, Paul Rodney Clayton, David Tosh, Fernando Felquer, Ralf Brandt